News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Servier Offers $483 Million to Buy Remaining Stake of Egis Pharmaceuticals PLC


9/24/2013 6:53:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Servier Voluntary Public Offer for all Outstanding Shares of Egis Pharmaceuticals PLC

LONDON, September 24, 2013 /PRNewswire/ -- Pascal Touchon, Head of Business Development and Scientific Cooperation, announced Servier Group's voluntary public offer for all outstanding shares of a majority-owned company, Egis, at a price of 28,000 HUF per share. Touchon added that Egis is their only affiliate to be listed on a stock exchange (BUX), and since the business does not require equity financing, "It makes little financial sense for Egis to maintain its presence on the stock market."

The Offer now needs to gain approval from the Hungarian Financial Supervisory Authority.

The video interview is available now on http://www.servier.com/.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@merchantcantos.com or phone +44-207-936-1352.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Servier
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES